Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II trial of IMU-838 in patients with Crohn's disease (CALDOSE-2).

Trial Profile

A Phase II trial of IMU-838 in patients with Crohn's disease (CALDOSE-2).

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Vidofludimus calcium (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms CALDOSE-2
  • Sponsors Immunic
  • Most Recent Events

    • 07 Jan 2019 According to a Vital Therapies media release, the company intends to initiate the trial throughout the course of 2019.
    • 15 Jan 2018 New trial record
    • 11 Jan 2018 According to an Immunic media release, the company is planning to commence this trial after receiving interim data from the Ulcerative colitis (UC) trial (CALDOSE-1).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top